SALT LAKE CITY, April 04, 2016 -- LifeVantage Corporation (Nasdaq:LFVN), announced today that it has entered into a new $10 million three-year term loan credit package with Zions Bank. Proceeds from the new credit agreement, along with cash on hand, will be used to repay the company’s existing higher interest rate term loan with TCW.
“We are very pleased to partner with Zions Bank on our new credit agreement,” said LifeVantage Chief Financial Officer, Mark Jaggi. “The new term loan offers a significantly reduced interest rate than our prior credit agreement, and more appropriately reflects our favorable financial position and strong cash flows.”
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing company dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, the TrueScience™ Anti-Aging Skin Care Regimen, Canine Health, the AXIO™ energy product line and the PhysIQ™ smart weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates", "look forward to", “goal”, “ideal fit”, and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our leadership in the global market, future growth and financial performance. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
Investor Relations Contact: Cindy England (801) 432-9036 Director of Investor Relations -or- Scott Van Winkle (617) 956-6736 Managing Director, ICR


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 



